John Hunt at the UK Centre for Tissue Engineering at the University of Liverpool and Duncan Graham at the Centre of Molecular NanoMetrology at the University of Strathclyde will act as principal investigators for the collaboration.
Leveraging NanoInk’s Dip Pen Nanolithography technology, it is now possible to produce differentiated homogenous stem cell populations which will lead to faster and more efficient drug discovery and development processes, with substantial cost savings, said NanoInk.
Jim Hussey, CEO of NanoInk, said: “We are extremely excited to join forces with these two esteemed institutions. We are eager to pursue the commercial potential of using nanotechnology to control stem cell function, particularly in the area of regenerative medicine.”